EUVIMEDEUVIMED entdecken
Kommentar

Small molecule. Big biology. Dual phosphatase inhibitor enters the immunotherapy fray

Nicholas S Wilson, Nicholas D Huntington iD

Immunology & Cell Biology · 2024

DOI: 10.1111/imcb.12711 ↗

Kurz gefasst

Kommentar in der Zeitschrift Immunology & Cell Biology, 2024. Verfasst von Nicholas S Wilson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Bristol Myers Squibb, Cancer Immunology and Cell Therapy Thematic Research Centre, Redwood City, CL, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The advent and clinical success of immune checkpoint inhibitors Ipilimumab, Nivolumab and Pembrolizumab has had a seismic impact on our drug discovery focus and rationale. Novel extrinsic targets that enhance immune responses to cancer are actively being pursued, while tumor intrinsic targets that render cancer cells more sensitive to the immune system have joined traditional intrinsic targets (e.g. directly cytotoxic) in the drug discovery pipeline. The phosphatase PTPN2 (TC‐PTP) and its paralog PTPN1 (PTP‐1B) are negative regulators of several cytokine signaling pathways and T cell receptor (TCR) signaling. In a recent publication, Baumgartner et al. demonstrate the pre‐clinical efficacy of a first‐in‐class dual PTPN1/N2 active site inhibitor (ABBV‐CLS‐484/AC484) in cancer models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalNeoplasmsHumansNivolumabIpilimumabImmunotherapyBiology

Stichwörter der Autor:innen

CD8 T cellsIFNgcancer immunotherapycytokine receptorsphosphatases

Substanzen

Antibodies, MonoclonalNivolumabIpilimumab

Autor:innen und Institutionen

  • Bristol Myers Squibb, Cancer Immunology and Cell Therapy Thematic Research Centre, Redwood City, CL, USA.
  • oNKo-Innate Pty Ltd, Melbourne, VIC, 3000, Australia.

ORCID-Profile: Nicholas D Huntington

Zitieren

APA

Wilson, N. S., & Huntington, N. D. (2024). Small molecule. Big biology. Dual phosphatase inhibitor enters the immunotherapy fray. Immunology & Cell Biology. https://doi.org/10.1111/imcb.12711

Vancouver

Wilson NS, Huntington ND. Small molecule. Big biology. Dual phosphatase inhibitor enters the immunotherapy fray. Immunology & Cell Biology. 2024. doi:10.1111/imcb.12711

BibTeX
@article{Wilson2024,
  author = {Wilson, Nicholas S and Huntington, Nicholas D},
  title = {Small molecule. Big biology. Dual phosphatase inhibitor enters the immunotherapy fray},
  journal = {Immunology & Cell Biology},
  year = {2024},
  doi = {10.1111/imcb.12711}
}
Kostenlos starten →